Drug
navenibart
navenibart is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Completed1
Enrolling by invitation1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed133%
enrolling_by_invitation133%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
enrolling_by_invitationphase_3
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938
active_not_recruitingphase_3
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823
completedphase_1
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
NCT05695248
Clinical Trials (3)
Showing 3 of 3 trials
NCT07204938Phase 3
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Phase 3
A Study of Navenibart in Participants With Hereditary Angioedema
NCT05695248Phase 1
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3